GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK prepares for patent cliff with $2.5B cost-cutting plan
GSK
Services: Pharmaceutical medicines, vaccines, consumer healthcare; specialty medicines in HIV, oncology, respiratory; vaccines for hepatitis, HPV, meningitis.
Company Info
Sector:Pharmaceuticals / Vaccines & Specialty
Headquarters:London, United Kingdom
Founded:2000
Website:www.gsk.com/en-gb/
Upcoming Milestones & Key Dates
Q3/Q4 2026
Earnings
Q2 2026 earnings call
Recent News
GSK, AI biotech Relation pen $110M biological datasets pact
GSK, AI biotech Relation pen $110M biological datasets pact
GSK lung cancer drug gets speedy approval following $10.6B deal
GSK's Jideytro (belantamab) regimen won FDA accelerated approval for ROS1-positive lung cancer, validating the company's $10.6B acquisition earlier this year.
GSK's $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
GSK's $10.6 billion Nuvalent bet pays off early as the FDA approves its lung cancer drug.
Nuvalent deal delivers GSK's first-ever lung cancer approval
GSK's $10.6B Nuvalent deal delivers its first-ever lung cancer FDA approval with Jideytro (zidesamtinib) for ROS1-positive NSCLC.
GSK shelves cough drug acquired in $2B deal
GSK is shelving its cough drug camlipixant that it acquired in a $2 billion deal.
$10B M&A Deal Pays Off With GSK's First Lung Cancer Drug Approval
A $10 billion M&A deal pays off with GSK's first lung cancer drug FDA approval (Jideytro / zidesamtinib).
Leadership Team
Careers & Job Openings